Tadalafil Tablet
Product Images NDC 68071-3758

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3758). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3758 7)

Label for Tadalafil 10 mg oral tablets by NuCare Pharmaceuticals, Inc. The package contains 5 almond-shaped yellow tablets debossed with '050'. The label includes manufacturer information, NDC 68071-3758-7, storage instructions, and warnings to keep out of reach of children. It also presents serial, lot, and expiration details along with a bar code and QR code.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework with various rings and functional groups as depicted in the image.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This figure contains four line graphs showing blood pressure differences (Tadalafil minus Placebo) over time in hours. The graphs present changes in standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, with values on the y-axis and time in hours on the x-axis, including error bars for variability.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

A dual-line graph showing changes in systolic blood pressure (mmHg) over time (hours) post-dose up to 24 hours. The top chart presents standing systolic blood pressure with two lines: tadalafil 20 mg & doxazosin 8 mg versus placebo & doxazosin 8 mg. The bottom chart shows supine systolic blood pressure with the same two comparisons, indicating fluctuations and recovery of blood pressure levels over time.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph depicting systolic blood pressure (mmHg) over a 12-hour period after administration of tadalafil or placebo combined with doxazosin. The graph compares four groups: 20 mg tadalafil at 8:00 with 8 mg doxazosin, placebo at 8:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin, showing variations in systolic blood pressure over time.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after five consecutive days. The graph shows concentration decreasing over 120 hours with error bars indicating variability at each time point.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph showing change from baseline in IPSS Total Score over a 12-week treatment period comparing tadalafil tablets 5 mg and placebo. The x-axis represents treatment duration in weeks (0, 4, 8, 12), and the y-axis shows score change. Tadalafil shows a greater decrease over time compared to placebo, with statistical significance indicated at 12 weeks (p < 0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment period comparing tadalafil 5 mg tablets to placebo. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows the change in score, with tadalafil showing a greater decrease over time relative to placebo. Statistical significance is indicated at week 4 and week 12.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph showing the least squares mean change from baseline over weeks of therapy (0, 4, 12, 26) comparing Tadalafil/Finasteride versus Placebo/Finasteride treatments. The graph includes markers and notes on statistical significance at various points during the study period.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph depicting changes from baseline in IPSS Total Score over 12 weeks of treatment. It compares tadalafil tablets 5 mg and placebo, showing greater reductions in scores with tadalafil. The x-axis represents treatment duration in weeks, and the y-axis represents change in score, with a statistically significant difference annotated at 12 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.